✦ LIBER ✦

Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy

✍ Scribed by Thomas J. Sayers; William J. Murphy

Book ID: 105967014
Publisher: Springer-Verlag
Year: 2005
Tongue: English
Weight: 342 KB
Volume: 55
Category: Article
ISSN: 0340-7004
DOI: 10.1007/s00262-005-0676-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

TNF-related apoptosis-inducing ligand (T

✍ Cretney, Erika; McQualter, Jonathan L; Kayagaki, Nobuhiko; Yagita, Hideo; Bernar 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 469 KB

Characterization of the in vivo function

Characterization of the in vivo function of TNF-α-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice

✍ Lisa M. Sedger; Moira B. Glaccum; JoAnn C. L. Schuh; Suzanne T. Kanaly; Eilidh W 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 227 KB 👁 1 views

TNF-related apoptosis inducing ligand (T

✍ H. Wajant; K. Pfizenmaier; P. Scheurich 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 254 KB

Resistance of prostate cancer cells to s

Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL

✍ Voelkel-Johnson, Christina; King, Deanne Lea; Norris, James Scott 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 1013 KB

Combining naturally occurring polyphenol

Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells?

✍ Guillaume Jacquemin; Sarah Shirley; Olivier Micheau 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 524 KB

Preparation and characterization of Apo2

Preparation and characterization of Apo2L/TNF-related apoptosis-inducing ligand–loaded human serum albumin nanoparticles with improved stability and tumor distribution

✍ Tae Hyung Kim; Hai-Hua Jiang; Yu Seok Youn; Chan Woong Park; Sung Mook Lim; Chen 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 481 KB

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has received considerable attention as a potential anticancer agent. However, recombinant Apo2L/TRAIL has several limitations, which include a weak pharmacokinetic profile, namely, a short biological half-life and rapid renal clearance,